People · Operator
Named in public records as an officer, director or promoter · active 2009–2009 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Normoxys, Inc. | — | Biotechnology | Series B | $25.3M | $23.8M | 2009 |
DR. JEAN-PIERRE GARNIER at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside DR. JEAN-PIERRE GARNIER on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Clark | 1 | 8 |
| Michele Ollier | 1 | 4 |
| Francesco De Rubertis | 1 | 4 |
| Martin Tolar | 1 | 2 |
| Jean-Pierre Garnier | 1 | 2 |
| SARA MCKENZIE | 1 | 1 |
| CONRAD J. BLETZER, JR. | 1 | 1 |
| ARGERIS KARABELAS | 1 | 1 |
| CONRAD BLETZER, JR. | 1 | 1 |
| CLAUDE NICOLAU | 1 | 1 |
| JEAN-MARIE LEHN | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.